Summary The role of glutathione (GSH) in resistance to cisplatin (CDDP) was studied in a human small cell lung carcinoma cell line (GLC4) and a CDDP-resistant subline (GLC4-CDDP). In addition to studying the steady state of GSH, the kinetics of this defence system were also studied via the monitoring of the GSH status of the cells under continuous pressure of CDDP. GLC4-CDDP maintained its elevated GSH level whereas GLC4 (under pressure of CDDP) quickly synthesised GSH to about twice its intitial level, corresponding with 80% of the GSH level of GLC4-CDDP. D,L-buthionine-S,R-sulphoximine (BSO) was used to analyse the role of GSH in resistance to CDDP. Pretreatment with BSO (48 h, 50 tAM, GSH not detectable) increased the CDDP-induced cytotoxicity 2.8-fold in GLC4-CDDP and 1.7-fold in GLC4. In GLC4 no changes in the amount of platinum (Pt) bound to DNA could be observed after GSH depletion. Changes in formation of interstrand cross-links or the main Pt-containing intrastrand cross-link in digested DNA, the Pt-GG adduct, were also not observed. In GSH depleted GLC4-CDDP cells, an increase in the amount of Pt bound to DNA and in the Pt-GG adduct was observed. Pretreatment with BSO substantially reduced the repair of Pt bound to DNA in both cell lines. We conclude that an increased GSH level and GSH synthesis capacity were demonstrated in CDDP resistant cells. The observations after BSO treatment suggest two roles for GSH in CDDP resistance, namely that of a cytosolic elimination resulting in less DNA platination and a nuclear effect on the formation and repair of DNA platinum adducts.
The development of acquired resistance to the useful antineoplastic drug cisplatin (CDDP) is a major limitation to the drug's clinical use. Several mechanisms responsible for this resistance to CDDP including reduced membrane permeability, enhanced drug detoxification, changes at the level of DNA adduct formation and increased efficiency of DNA repair have been previously reported (Teicher et al., 1987; Richon et al., 1987; Waud, 1987; Kraker & Moore, 1988; Andrews et al., 1988; Hamilton et al., 1985; Hromas et al., 1987; Behrens et al., 1987; Eastman & Schulte, 1988) .
There is growing evidence that glutathione (GSH), the major cellular non-protein thiol, may play an important role in cellular resistance to several chemotherapeutic agents (Arrick & Nathan, 1984; Green et al., 1984; Tan et al., 1987; Evans et al., 1987; Hospers et al., 1988) . Its roles in CDDP resistance, however, remains controversial. CDDP is sufficiently electrophilic to react directly with GSH (Eastman, 1987) , resulting in a decrease in the level of drug metabolites that can react with critical intracellular targets such as DNA. An increased GSH level, therefore, could protect cells in an early stage of exposure to CDDP. The consumption of GSH in this reaction then affects the GSH production cycle. Since the effects of this burden on GSH economy are unknown we chose to study the possibility that resistant cells might handle their GSH status in a way different from that of sensitive cells. It has also been reported that CDDP resistance may be mediated by quenching of DNA-platinum mono adducts by GSH (Micetich et al., 1983) favoured by an increase in cellular GSH content.
To analyse the role of GSH in resistance to CDDP we used D,L-buthionine-S,R-sulphoximine (BSO) to block GSHsynthesis and studied a number of critical events after exposure to CDDP. This article reports on research aimed at evaluating: cellular and nuclear GSH, CDDP-induced cytotoxicity, cellular platinum (Pt) levels, the amount of Pt bound to DNA, the number of interstrand cross-links, the Pt-GG adduct content (the main Pt-containing intrastrand cross-link in digested DNA) and the repair of the amount of Pt bound to DNA in a CDDP sensitive and resistant human small cell lung cancer cell line.
Materials and methods

Chemicals
CDDP was provided by Bristol Myers SAE, Madrid, Spain. RPMI 1640 medium was obtained from Gibco, Paisley, UK. Fetal calf serum was obtained from Flow Lab, Irvine, UK. GSH, 1-chloro-2,4-dinitrobenzene (CDNB), 5,5-dithiobis (2-nitrobenzoic acid), ethylene glycol-bis(P-amino ethyl ether)N,N,N',N'-tetra acetic acid (EGTA), Triton X-100, (3- [4,5-dimethyl-thiazol-2y1 ]2,5-diphenyltetrazoliumbromide) (MTT) and DNAse I were obtained from Sigma (St Louis, MO), dimethyl sulphoxide and Proteinase K from Merck (Darmstadt, FRG), BSO from Chemalog (South Plainfield, NJ), nuclease P1 from Boehringer (Mannheim, FRG), ethidium bromide from Serva (Heidelberg, FRG), and 3H-thymidine (1 mCi ml-') from New England Nuclear (Boston, MA).
Cell lines GLC4, a human small cell lung cancer cell line and a CDDP resistant subline, GLC4-CDDP, characterised before by Hospers et al. (1988) , were cultured in RPMI 1640 medium with 10% heat-inactivated fetal calf serum at 37°C, 5% CO2. GLC4-CDDP was cultured under constant challenge of a monthly dose of 75 lg ml' CDDP. During the period in which the experiments for this study were performed, doubling times were 16 h and 28 h for GLC4 and GLC4-CDDP, respectively. Total GSH levels were 4.6 ± 0.5 and ROLE OF GLUTATHIONE IN CISPLATIN RESISTANCE 73 indication of growth delay or loss of viability could be observed.
GSH
Cells in the logarithmic phase of growth were harvested 4 days after passage. Cells were washed with ice-cold phosphate buffered saline (PBS) and resuspended in a relevant concentration. All measurements were performed under Vmax conditions. For cellular GSH determination, cells were resuspended in ice-cold 5% trichloroacetic acid (TCA), mixed vigorously and centrifuged at 4°C (5 min, 10,000 g). The supernatant was assayed for total GSH through enzyme recycling under conditions similar to those described by Tietze (1969) . The detection limit was 0.1 I g mg'-protein.
For nuclear GSH, nuclei were isolated according to the method described by Pommier et al. (1983) . Cells were washed twice with ice-cold PBS and resuspended in a 1/10 volume nucleus buffer (150 mM NaCI, 1 mM KH2PO4, 5 mM MgCl2, 1 mM EGTA and 0.1 mM dithiothreitol, pH 6.4) at 4°C. Then 9/10 volume of nucleus buffer containing 0.3% Triton X-100 at 4°C was added and the mixture was incubated for 10min at 4°C. The nuclei were pelleted by centrifugation and resuspended in nucleus buffer at 4°C. Nuclei were examined microscopically after staining with trypan blue to confirm the recovery of nuclei and the absence of cytoplasm. Nuclei were then resuspended in ice-cold 5% TCA, mixed vigorously and centrifuged at 4°C (15 min, 10,000 g). The supernatant was assayed for total GSH as described above.
For protein determination the Lowry assay was used (Lowry et al., 1951 The amount of Pt bound to the DNA was measured after treating 5 x 107 cells with CDDP concentrations ranging from 83 to 500 gM for 4 h. The cells were washed three times with PBS at 4°C, and the DNA was isolated by using the technique described by Fichtinger-Schepman et al. (1987) . Briefly, a phenol extraction and ethanol precipitation was followed by RNase treatment. The remaining proteins were extracted by chloroform/iso-amylalcohol. After isolation, the DNA was dissolved 1 N HCI. The DNA content was estimated by absorption at 260 nm; the amount of Pt in the sample was estimated by AAS as described by Roberts and Fraval (1980) . At least three independent experiments were performed at each CDDP concentration.
Pt-GG adduct The Pt-GG was measured by AAS after treating the cells with CDDP for 4 h. DNA was isolated from 5 x 10' cells after CDDP treatment and subsequent washing with PBS, as described earlier. After digestion of DNA, to 350 p1l DNA solution in distilled H20, 39 p1 of buffer was added (100 mM Tris-HCI, 40 mm MgCI2, 1 mM Na2EDTA) supplemented with 9.4 p11 O mm ZnSo4, 14 p1 DNAse I (3,000 U ml-') and 39 itl Nuclease P1 (1 mg ml-'), the mixture was incubated at 37°C overnight after which 25 1l proteinase K (18 mg ml-') was added. This was followed by incubation for another 2 h at 37C. Subsequently, the digest was heated for 5 min at 100C and, after the addition of 20.3 iLl 1 M Tris-HCI, centrifuged in an Eppendorf centrifuge for 2 min), the adduct was separated by anion-exchange column chromatography on the Mono Q HR 5/5 column having a particle size of 10 gM (Pharmacia, Uppsala, Sweden) according to the method described by Fichtinger-Schepman et al. (1987) . The Pt-GG adduct content in the eluate fractions were determined by Pt measurements with AAS. The total DNA content of a sample was estimated by absorption at 260 nm (FichtingerSchepman et al., 1985) . At least three independent experiments were performed at each CDDP concentration. DNA interstrand cross-links (ISC) Cells were incubated for 4 h with CDDP concentrations ranging from 83 to 500 gM and washed with PBS at 4°C three times. The pellets were subsequently resuspended and divided into two parts. The amount of ISC formed was measured with the ethidium bromide fluorescence assay, as described by de Jong et al. (1986) . After lysation for 15 h and the addition of the ethidium bromide, the DNA in one part of each sample was denatured by boiling followed by rapid cooling. The other part was kept at room temperature. The fluorescence of both parts was measured in a Kontron spectrofluorometer (excitation 525 nm, emission 580 nm). The fluorescence in the denatured part is related to the amount of ISC formed. The fluorescence in the other part is related to the total amount of DNA present in that particular sample.
Repair of DNA-Pt The removal of the amount of Pt bound to DNA was measured after incubating 108 cells per sample for 4 h with 33 gM CDDP (the maximal tolerable dose of CDDP without inducing cell toxicity at t = 22 h of the repair period). This procedure was followed by harvesting cells for total Pt-DNA binding. After CDDP treatment, half of the sample (repair t = 0 h) was washed three times with ice-cold PBS, pelleted by centrifugation and frozen. The other sample was washed twice with medium (37°C) and resuspended in fresh medium for a repair period of 22 h after which the cells were washed, pelleted and frozen as just above. At least three separate experiments, each in duplicate, were performed.
Correction for dilution by DNA synthesis Since the repair of the amount of Pt bound to DNA was quantified per mg of isolated DNA, correction for dilution by DNA synthesised during the 22 h post-treatment incubated period was carried out according to the method described by Bedford et al. (1988) . Cells were labelled for 44 h with 20nCiml1' 3H-thymidine followed by 4h in isotopefree medium. Cells were then exposed for 4 h to 33 LM CDDP, as described previously, and harvested either immediately or after 22 h. DNA was extracted by heating the cell pellets at 70°C for 1 h in 1 N perchloric acid. Radioactivity was determined in 200 jul aliquots of supernatant and the DNA content of the remainder was estimated spectrophotometrically as described above. The dilution factor was calculated as the specific activity of DNA at 22 h divided by the specific activity of DNA at 0 h. The apparent amount of Pt bound to DNA at 22 h divided by the dilution factor gave the amount of Pt bound to DNA.
Statistics
Statistical significance was determined with the unpaired Student's t test and for the BSO experiments with the paired Student's t test. P values <0.05 were considered significant.
Results
Survival curves of GLC4 and GLC4-CDDP after 50 jM BSO for 48 h showed an increased CDDP induced cytotoxicity after 4 h of CDDP treatment (Figure 1) . IC5o values were 1.0IM and 221M for GLC4 and GLC4-CDDP respectively and decreased to 0.6 tM and 7.8 gM respectively. BSO modulated CDDP survival in the sensitive cell line by a factor of 1.7 and in the CDDP resistant cell line by a factor of 2.8. Dose modifying factors (DMF) were calculated at the ICIO, IC20, ..., IC90 for both cell lines to confirm a significantly higher BSO modulating effect on the CDDP induced cytotoxicity in GLC4-CDDP compared to GLC4. DMF, obtained from the separate survival curves, were 1.90 ± 0.63 (n = 21) and 3.03 ± 1.51 (n = 26) in GLC4 and GLC4-CDDP respectively (P <0.0025). Nuclear GSH contents were 89 ± 12 ng mg-' cellular protein and 235 ± 138 ng mg-' cellular protein (mean ± s.d., n = 3) in GLC4 and GLC4-CDDP respectively (P <0.05). The elevated nuclear GSH in GLC4-CDDP compared to GLC4 is proportional to the elevated cellular GSH in GLC4-CDDP compared to GLC4. Figure 3 . Following BSO pretreatment, an increased Pt-DNA binding for GLC4-CDDP was seen whereas the Pt-DNA binding in GLC4 remained the same. In GLC4-CDDP a reduced number of ISC was observed as compared to GLC4. Figure 4 shows the effect of pretreatment with BSO on the ISC formation. Although an increase in ISC seemed to appear in GLC4-CDDP after BSO pretreatment, no significant change in formation could be confirmed. The initial decreased formation of ISC in the resistant cell line when compared to the sensitive line could be eliminated. The effect of pretreatment with BSO on the formation of the Pt-GG adduct is shown in Figure 5 . A significant increase in Pt-GG adduct formation (2.6-fold) after pretreatment with BSO was observed in GLC4-CDDP whereas the Pt-GG adduct formation after pretreatment with BSO remained the same for GLC4. Table I shows the repair capacity of GLC4 and GLC4-CDDP after incubation for 4 h with 33 t4M CDDP followed by a drug-free culture period of 22 h. Both GLC4 and GLC4-CDDP showed a significant reduction in the amount of Pt bound to DNA after the 22 h drug-free culture period. Significantly different values were observed for GLC4-CDDP versus GLC4 at all tested concentrations: at 83 JAM, P <0.005; at 167 IM, P < 0.005; at 333JM, P < 0.025; and at 500 M, P <0.0005. No significant changes were observed in either cell line following BSO treatment. 
Discussion
Given the sulphydryl reactive properties of CDDP, alterations in cellular thiol content may be a defence mechanism generated in CDDP resistant cells. GSH, the main nonprotein thiol present in cells, has been shown to be an important determinant of the sensitivity of cells to a wide variety of drugs including cytostatic agents (Arrick & Nathan, 1984) . Elevated levels of GSH have been associated with drug-resistant phenotypes developed in cells exposed to a number of electrophilic drugs (Hamilton et al., 1985; Green et al., 1984; Tan et al., 1987; Evans et al., 1987) . Moreover, cells with elevated levels of GSH also appeared to be resistant to CDDP (Richon et al., 1987; Waud, 1987; Hamilton et al., 1985; Hromas et al., 1987; Behrens et al., 1987) . However, when BSO is used to deplete GSH levels, the effect on CDDP induced cytotoxicity varied in the different studies. In the cell lines used in this study, the CDDP resistant subline GLC4-CDDP had a 2.5-fold increase in GSH content as compared to the CDDP sensitive cell line. Exposure of the cells to BSO reduced the cellular GSH content to a nondetectable level in both cell lines and increased the CDDP induced cytotoxicity. This is in agreement with the findings of Hamilton et al. (1985) and Hromas et al. (1987) . In other studies, however, no effect of BSO on CDDP-induced cytotoxicity was found (Teicher et al., 1987; Richon et al., 1987) .
The exact mechanism by which GSH influences CDDP cytotoxicity is not yet completely clear. CDDP can be inactivated by direct binding to the sulphydryl moiety of GSH, thereby preventing the drug from reaching the critical DNA. This cytosolic inactivation should take place during the limited time prior to reaction with DNA.
The steady state of GSH is generally used to express the capacity of this defence system, although the kinetics of the GSH status should give the more dynamic representation of the continuous availability of this defence. In the present study the GSH status was depicted under continuous pressure of CDDP. GLC4-CDDP was able to maintain its elevated GSH level under pressure of both 5.8 and 32 tLM CDDP suggesting an enhanced GSH biosynthetic capacity in GLC4-CDDP. GLC4 showed a fast synthesis of GSH under pressure of 5.8 tLM CDDP. After continuous incubation for 5 h with CDDP, the GSH level reached about twice its own original level, which corresponds to 80% of the GSH level of GLC4-CDDP (Figure 2 The role of GSH at the nuclear level is still unclear. Eastman (1987) showed that GSH can react in vitro with monofunctional adducts of platinated DNA and prevent them from rearranging to form toxic bifunctional adducts. The formation and protective role of this GSH-adduct is, however, still unclear.
Only small amounts of GSH could be detected in the nuclei of GLC4 and GLC4-CDDP. The elevation of nuclear GSH in GLC4-CDDP as compared to GLC4 is in proportion to the increased cellular GSH content of this cell line. Since some leakage of GSH can be assumed to occur from the nuclei during the isolation procedure, the nuclear GSH values are probably underestimated. However, Edgren and Revesz (1987) also detected less than 1% of the total GSH in the nuclei of Chinese hamster V79-379A cells. GSH depletion by BSO was also demonstrated by them to be more efficient in whole cells than in isolated nuclei for a period varying in length up to 18 h. In the present study no GSH could be detected in the nuclei of either GLC4 and GLC4-CDDP after a 48 h pretreatment with BSO.
ISC have been reported to be enhanced after BSO-induced GSH depletion in human leukaemia cells insensitive to activated cyclophosphamide (Crook et al., 1986) as well as human melanoma cells, which generally have a high degree of inherent resistance to bifunctional alkylating agents (Hansson et al., 1988 ). An effect of BSO on the induction of sister chromatid exchanges has also been published (Evans et al., 1987) . In this study, neither changes in the amount of Pt bound to DNA after GSH depletion, nor changes in the formation of ISC or Pt-GG adducts were observed in GLC4. In GSH depleted GLC4-CDDP cells, however, an increase in the amount of Pt bound to DNA was found. The main Pt-containing intrastrand cross-link in digested DNA, the Pt-GG adduct, also increased after GSH depletion. The difference in formation of ISC between GLC4 and GLC4-CDDP was annihilated by pretreatment with BSO ( Figures  3-5) .
Lai et al. (1989) recently described that, aside from the generally considered BSO effects on alkylating agents related to GSH reduction, BSO treatment partially inhibited DNA repair after CDDP damage in an ovarian cancer cell line with in vitro induced resistance to CDDP, as measured by unscheduled DNA synthesis.
In the present study, the repair of the amount of Pt bound to DNA was assayed at an incubation concentration of 33 ILM CDDP for 4 h. Under these conditions, repair of the amount of Pt bound to DNA could be observed in both GLC4 and GLC4-CDDP, a capacity which was earlier described to be only operational in the GLC4-CDDP line with a resistance factor of 11 (Hospers et al., 1990) , most probably due to the treatment schedule (t = 2 h compared to t =4 h) in combination with a high CDDP concentration (especially for GLC4) used in the previous study. After GSH depletion, both cell lines were unable to repair the CDDP induced amount of Pt bound to DNA. The elimination of the quenching of monofunctional DNA adducts by GSH, resulting from BSO pretreatment, may be an explanation for the loss of repair capacity in both cell lines.
A disparity in concentrations used for the various parameters due to the detection limit for Pt as measured by AAS was unavoidable. Taking this into account, we conclude that an increased GSH level and GSH synthesis capacity was demonstrated in CDDP resistant cells. The observations after BSO treatment, namely the 2.6-fold increase in the CDDP induced cytotoxicity in GLC4-CDDP, suggest two roles for GSH in CDDP resistance, namely a cytosolic elimination resulting in less DNA platination, and a more pronounced nuclear effect on the formation and repair of DNA platinum adducts. The still remaining thirteen-fold resistance after BSO treatment in these CDDP resistant cell lines, however, should dispute the 'relative' importance of this GSH mediated CDDP resistance in perspective with the other mechanisms that are operative in this line, such as a decreased total DNA platination, a decreased Pt-GG adduct formation, a decreased ISC formation and/or a more efficient DNA repair.
